• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺乳头状癌中HER2扩增与端粒缩短的基因异质性

Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma.

作者信息

Caria Paola, Cantara Silvia, Frau Daniela Virginia, Pacini Furio, Vanni Roberta, Dettori Tinuccia

机构信息

Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, Monserrato 09042, Italy.

Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena 53100, Italy.

出版信息

Int J Mol Sci. 2016 Oct 21;17(10):1759. doi: 10.3390/ijms17101759.

DOI:10.3390/ijms17101759
PMID:27775641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5085783/
Abstract

Extensive research is dedicated to understanding if sporadic and familial papillary thyroid carcinoma are distinct biological entities. We have previously demonstrated that familial papillary thyroid cancer (fPTC) cells exhibit short relative telomere length (RTL) in both blood and tissues and that these features may be associated with chromosome instability. Here, we investigated the frequency of () amplification, and other recently reported genetic alterations in sporadic PTC (sPTC) and fPTC, and assessed correlations with RTL and mutational status. We analyzed gene amplification and the integrity of , , , and genes by fluorescence in situ hybridization in isolated nuclei and paraffin-embedded formalin-fixed sections of 13 fPTC and 18 sPTC patients. We analyzed mutation and RTL by qRT-PCR. Significant amplification ( = 0.0076), which was restricted to scattered groups of cells, was found in fPTC samples. amplification in fPTCs was invariably associated with mutation. RTL was shorter in fPTCs than sPTCs ( < 0.001). No rearrangements of other tested genes were observed. These findings suggest that the association of amplification with mutation and telomere shortening may represent a marker of tumor aggressiveness, and, in refractory thyroid cancer, may warrant exploration as a site for targeted therapy.

摘要

大量研究致力于了解散发性和家族性甲状腺乳头状癌是否为不同的生物学实体。我们之前已经证明,家族性甲状腺乳头状癌(fPTC)细胞在血液和组织中均表现出较短的相对端粒长度(RTL),并且这些特征可能与染色体不稳定性有关。在此,我们研究了散发性甲状腺乳头状癌(sPTC)和fPTC中()扩增以及其他最近报道的基因改变的频率,并评估了与RTL和突变状态的相关性。我们通过荧光原位杂交在13例fPTC和18例sPTC患者的分离细胞核及石蜡包埋的福尔马林固定切片中分析了基因扩增以及、、和基因的完整性。我们通过qRT-PCR分析了突变和RTL。在fPTC样本中发现了显著的扩增(= 0.0076),其仅限于散在的细胞群。fPTC中的扩增总是与突变相关。fPTC中的RTL比sPTC中的短(< 0.001)。未观察到其他测试基因的重排。这些发现表明,扩增与突变以及端粒缩短之间的关联可能代表肿瘤侵袭性的一个标志物,并且在难治性甲状腺癌中,可能值得探索作为靶向治疗的位点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/067c/5085783/9280f40cc33a/ijms-17-01759-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/067c/5085783/8eaf73fe93e0/ijms-17-01759-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/067c/5085783/ce5b51bad5aa/ijms-17-01759-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/067c/5085783/2d456e763c0a/ijms-17-01759-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/067c/5085783/9280f40cc33a/ijms-17-01759-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/067c/5085783/8eaf73fe93e0/ijms-17-01759-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/067c/5085783/ce5b51bad5aa/ijms-17-01759-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/067c/5085783/2d456e763c0a/ijms-17-01759-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/067c/5085783/9280f40cc33a/ijms-17-01759-g004.jpg

相似文献

1
Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma.甲状腺乳头状癌中HER2扩增与端粒缩短的基因异质性
Int J Mol Sci. 2016 Oct 21;17(10):1759. doi: 10.3390/ijms17101759.
2
Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients.家族性甲状腺乳头状癌患者血液中的短端粒、端粒酶逆转录酶基因扩增及端粒酶活性增加。
J Clin Endocrinol Metab. 2008 Oct;93(10):3950-7. doi: 10.1210/jc.2008-0372. Epub 2008 Jul 29.
3
Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.甲状腺乳头状癌中常同时出现 BRAF(V600E) 突变和 RET/PTC 重排。
Thyroid. 2014 Feb;24(2):254-9. doi: 10.1089/thy.2013.0235. Epub 2013 Aug 24.
4
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.有证据表明,一部分间变性甲状腺癌是由于BRAF和p53突变而由乳头状癌演变而来。
Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073.
5
Amplification of the human epidermal growth factor receptor 2 gene in differentiated thyroid cancer correlates with telomere shortening.人表皮生长因子受体 2 基因在分化型甲状腺癌中的扩增与端粒缩短相关。
Int J Oncol. 2013 May;42(5):1589-96. doi: 10.3892/ijo.2013.1848. Epub 2013 Mar 5.
6
Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.融合致癌基因是儿童散发性乳头状甲状腺癌中发现的主要基因事件。
Thyroid. 2017 Feb;27(2):182-188. doi: 10.1089/thy.2016.0387. Epub 2016 Dec 27.
7
[Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].[甲状腺乳头状癌中RET/PTC重排和BRAF体细胞突变的频率]
Vopr Onkol. 2006;52(2):145-9.
8
Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.塞尔维亚甲状腺乳头癌的突变与临床病理分析。
Endocr J. 2011;58(5):381-93. doi: 10.1507/endocrj.k11e-054. Epub 2011 Apr 15.
9
Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.通过BRAF V600E突变和RET/PTC重排的细针穿刺分子分析诊断甲状腺乳头状癌
Thyroid. 2007 Nov;17(11):1109-15. doi: 10.1089/thy.2007.0008.
10
Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer.家族性和散发性甲状腺乳头状癌患者的肿瘤和非肿瘤组织中的端粒长度。
J Clin Endocrinol Metab. 2011 Nov;96(11):E1852-6. doi: 10.1210/jc.2011-1003. Epub 2011 Aug 24.

引用本文的文献

1
A Comprehensive Diagnostic Assessment of Thyroid Nodules Utilizing Scintigraphy and Telomere Lengths (T/S ratios).利用闪烁扫描法和端粒长度(T/S 比值)对甲状腺结节进行综合诊断评估。
Mol Imaging Radionucl Ther. 2025 Jun 3;34(2):97-106. doi: 10.4274/mirt.galenos.2025.85429.
2
ERBB2 as a prognostic biomarker correlates with immune infiltrates in papillary thyroid cancer.ERBB2作为一种预后生物标志物与甲状腺乳头状癌中的免疫浸润相关。
Front Genet. 2022 Nov 9;13:966365. doi: 10.3389/fgene.2022.966365. eCollection 2022.
3
Three-dimensional telomere profiles in papillary thyroid cancer variants: A pilot study.

本文引用的文献

1
Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality.通过联合检测BRAF V600E和TERT启动子突变对甲状腺乳头状癌进行死亡风险分层:BRAF和TERT启动子突变在甲状腺癌死亡中的基因二重奏
JAMA Oncol. 2017 Feb 1;3(2):202-208. doi: 10.1001/jamaoncol.2016.3288.
2
Identification of Neuroblastoma Subgroups Based on Three-Dimensional Telomere Organization.基于三维端粒组织的神经母细胞瘤亚组鉴定
Transl Oncol. 2016 Aug;9(4):348-56. doi: 10.1016/j.tranon.2016.07.001.
3
HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
甲状腺乳头癌变异体中的三维端粒谱:一项初步研究。
Bosn J Basic Med Sci. 2022 Jun 1;22(3):481-487. doi: 10.17305/bjbms.2021.6639.
4
Distribution and Prognostic Significance of Estrogen Receptor (ER), Estrogen Receptor (ER), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma.雌激素受体(ER)、雌激素受体(ER)和人表皮生长因子受体2(HER-2)在甲状腺癌中的分布及预后意义
J Thyroid Res. 2020 May 5;2020:6935724. doi: 10.1155/2020/6935724. eCollection 2020.
5
Telomerase and Telomeres Biology in Thyroid Cancer.甲状腺癌中端粒酶和端粒生物学。
Int J Mol Sci. 2019 Jun 13;20(12):2887. doi: 10.3390/ijms20122887.
6
Current Knowledge in Thyroid Cancer-From Bench to Bedside.甲状腺癌的当前知识——从实验室到临床
Int J Mol Sci. 2017 Jul 15;18(7):1529. doi: 10.3390/ijms18071529.
7
HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin.HER2在滤泡细胞起源的散发性甲状腺癌中的分析
Int J Mol Sci. 2016 Dec 6;17(12):2040. doi: 10.3390/ijms17122040.
HABP2种系变异在家族性非髓样甲状腺癌中并不常见。
BMC Med Genet. 2016 Aug 17;17(1):60. doi: 10.1186/s12881-016-0323-1.
4
Targeted therapies in thyroid cancer: an extensive review of the literature.甲状腺癌的靶向治疗:文献综述
Expert Rev Clin Pharmacol. 2016 Oct;9(10):1299-1313. doi: 10.1080/17512433.2016.1204230. Epub 2016 Jul 15.
5
RE: HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.关于:家族性非髓样甲状腺癌中的HABP2 G534E突变。
J Natl Cancer Inst. 2016 May 6;108(8). doi: 10.1093/jnci/djw108. Print 2016 Aug.
6
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.低分化和间变性甲状腺癌的基因组和转录组特征
J Clin Invest. 2016 Mar 1;126(3):1052-66. doi: 10.1172/JCI85271. Epub 2016 Feb 15.
7
Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study.甲状腺功能减退症、甲状腺功能亢进症与乳腺癌风险:一项全国性队列研究。
Eur J Endocrinol. 2016 Apr;174(4):409-14. doi: 10.1530/EJE-15-0989.
8
HABP2 G534E Variant in Papillary Thyroid Carcinoma.甲状腺乳头状癌中的HABP2 G534E变异体
PLoS One. 2016 Jan 8;11(1):e0146315. doi: 10.1371/journal.pone.0146315. eCollection 2016.
9
TERT promoter mutations in thyroid cancer.甲状腺癌中的端粒酶逆转录酶(TERT)启动子突变
Endocr Relat Cancer. 2016 Mar;23(3):R143-55. doi: 10.1530/ERC-15-0533. Epub 2016 Jan 5.
10
Thyroid cancer in 2015: Molecular landscape of thyroid cancer continues to be deciphered.2015年的甲状腺癌:甲状腺癌的分子格局仍在不断被破解。
Nat Rev Endocrinol. 2016 Feb;12(2):67-8. doi: 10.1038/nrendo.2015.217. Epub 2015 Dec 15.